The test can be used in point-of-care settings. Credit: Tatiana / Pixabay.

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the Xpert Mpox test from molecular diagnostics company Cepheid.

The authorisation enables the emergency use of in vitro diagnostics for the detection and diagnosis of infection with the monkeypox virus, which is supported by a declaration from the Secretary of Health and Human Services.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Designed to operate on the company’s GeneXpert systems, the test has received authorisation for use in moderately complex settings.

Under the EUA, Xpert Mpox is now authorised for use in point-of-care (POC) settings on the GeneXpert Xpress systems.

The test provides flexibility by being approved for use in settings operating under a CLIA Certificate of Waiver (CoW), Certificate of Registration (CoR), Certificate of Accreditation (CoA), or Certificate of Compliance (CoC), stated Cepheid.

The company is planning to commence shipping of the test in the US by the end of the month.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Cepheid chief scientific officer and executive vice-president David Persing said: “Thankfully, the threat of mpox in the United States has decreased dramatically since last summer. However, it is still circulating in many parts of the world making it important for healthcare providers to be ready for its potential re-emergence.

“Xpert Mpox runs on Cepheid’s GeneXpert systems, which has the largest installed base of any PCR-based molecular diagnostic platform, making this new test a valuable component within a preparedness plan that could be deployed quickly wherever accurate and actionable information is needed.”

Last May, Cepheid secured EUA from the FDA for its Xpert Xpress CoV-2 plus test, which can identify the virus that causes Covid-19.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact